Regeneron's Stock Falls as Skin Cancer Treatment Fails Trial Target

• The fianlimab-cemiplimab combination missed its primary endpoint of progression-free survival (PFS) in patients with advanced melanoma, despite a 5.1-month median improvement versus Keytruda
• An Evercore analyst called the results a 'worst-case scenario,' noting that while fundamental impact is limited, market sentiment would likely weaken further
• The trial tested fianlimab combined with Regeneron's approved drug cemiplimab (Libtayo) as a first-line treatment for advanced melanoma, a rapidly spreading form of skin cancer

Regeneron Stock Plunges on Failed Melanoma Trial

Regeneron Pharmaceuticals (REGN.O) shares dropped 11.8% in premarket trading on Monday, May 18, after the company announced its experimental skin cancer treatment failed to meet its primary endpoint in a late-stage clinical trial.

Trial Results

The combination therapy of fianlimab-cemiplimab did not achieve statistical significance in improving progression-free survival (PFS) in patients with advanced melanoma. While the treatment showed a numerical improvement of 5.1 months in median PFS compared to Merck's Keytruda, the results did not reach the threshold required for statistical significance.

The study evaluated fianlimab combined with Regeneron's already-approved drug cemiplimab (brand name Libtayo) as a first-line treatment for advanced melanoma, an aggressive form of skin cancer that spreads rapidly throughout the body.

Market Impact

Evercore analyst Cory Kasimov described the results as a "worst-case scenario," noting that while the fundamental business impact may be relatively limited currently, investor sentiment is likely to deteriorate further. The significant premarket decline reflects investor disappointment in the drug's failure to demonstrate superiority over the existing standard of care.

Context

Advanced melanoma represents a critical unmet medical need due to its aggressive nature and difficulty to treat once it spreads. The failed trial represents a setback for Regeneron's oncology pipeline, as the company had positioned this combination therapy as a potential competitor to established treatments like Merck's Keytruda.

The competitive landscape for melanoma treatments remains dominated by existing immunotherapies, and Regeneron's inability to demonstrate statistical improvement limits its market opportunity in this indication.